Today, shortly after the opening bell, FluoroPharma Medical announced that BFPET, its imaging agent for measuring cardiovascular blood flow, has been granted patent rights in Australia. BFPET is a novel cardiovascular blood flow imaging agent that, when used in conjunction with stress-testing, identifies patients with suspected and proven coronary artery disease (CAD). The patent expiration date is 2025.
Symptomatic coronary artery disease (CAD) affects millions of patients worldwide and, according to the World Health Organization, cardiovascular diseases are the leading causes of death and disability in the world. The demand for faster, more accurate diagnostic tools continuously drives the development of non-invasive techniques with increased sensitivity and accuracy for the detection and assessment of acute and chronic CAD.
“Phase I clinical trial for BFPET indicates that the compound has an acceptable dosimetry and safety profile and provides high resolution images of the heart,” commented Dr. David Elmaleh, FluoroPharma’s Chairman of the Board of Directors and inventor of the technology. “Since BFPET has the potential to be a more sensitive marker than the currently available blood flow agents, we believe that BFPET will have strong advantages over currently marketed products in the detection of acute and chronic ischemia.”
“The future for diagnostic imaging procedures with higher specificity is extremely promising as they provide early and more accurate information to enable more effective treatment and follow-up of its efficacy,” added Thijs Spoor, FluoroPharma’s President and Chief Executive Officer. “We look at this as an evolution to more effective and efficient care. Early treatment means saving the patient from long and expensive hospital stays, which results in less time away from family and work.”
In November of last year, FluoroPharma announced that it had been granted patent rights in China for BFPET and another imaging agent, AZPET, for imaging of Alzheimer’s disease. In addition to Australia and China, patents related to FluoroPharma’s portfolio of imaging compounds have been issued in the United States, Europe, Japan, Canada, Finland, Portugal, Ireland, and Mexico.
Today’s announcement enhances FluoroPharma’s position in the Pacific Rim and strengthens its growing patent estate, further validating the importance and value of FluoroPharma’s technology in important growth markets where diagnostic imaging is playing an increasingly significant role in the early detection of disease.
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
